| | Treatment | RR (95% CI) for ASAS40 response | SURCA for ASAS40 response, % | RR (95% CI) for ASAS20 response | SURCA for ASAS20 response, % | SMD (95% CI) for suppression of disease activity | SURCA for suppression of disease activity, % | SMD (95% CI) for improvement of daily living function | SURCA for improvement of daily living function, % | RR (95% CI) for withdrawal related to AEs | SURCA for withdrawal related to AEs, % | RR (95% CI) for incidence of SAEs | SURCA for incidence of SAEs, % |
| | Pla | Reference | 20.8 | Reference | 12.0 | Reference | 22.2 | Reference | 20.2 | Reference | 63.4 | Reference | 47.1 | | DMARDs | 1.13 (0.73, 1.75) | 28.9 | 1.38 (1.00, 1.90) | 34.8 | 1.08 (-1.71, 3.87) | 47.7 | 0.97 (-2.37, 4.31) | 48.8 | 1.48 (0.77, 2.85) | 34.2 | 0.90 (0.43, 1.90) | 52.9 | | IL6i | 0.60 (0.22, 1.67) | 6.6 | 1.36 (0.71, 2.58) | 37.6 | -0.16 (-5.43, 5.11) | 31.6 | NA | NA | 1.00 (0.02, 49.70) | 53.8 | 5.00 (0.25, 101.63) | 13.5 | | IL17Ai | 2.21 (1.75, 2.78) | 68.6 | 1.70 (1.44, 2.00) | 56.0 | 2.18 (0.45, 3.91) | 71.9 | 1.69 (-0.13, 3.52) | 64.7 | 1.42 (0.61, 3.27) | 39.3 | 0.72 (0.39, 1.33) | 67.5 | | IL17AFi | 3.44 (1.52, 7.79) | 91.4 | 2.55 (1.51, 4.29) | 92.5 | 0.96 (-4.31, 6.23) | 47.9 | 0.81 (-3.76, 5.39) | 46.1 | 1.97 (0.18, 21.31) | 33.0 | 0.20 (0.01, 4.01) | 83.9 | | IL23i | 0.98 (0.68, 1.40) | 19.9 | 0.91 (0.70, 1.19) | 5.2 | 0.03 (-2.61, 2.66) | 27.6 | -0.18 (-2.82, 2.45) | 23.6 | 0.58 (0.13, 2.58) | 76.4 | 0.52 (0.16, 1.65) | 76.2 | | JAKi | 1.89 (1.32, 2.71) | 57.4 | 1.76 (1.33, 2.34) | 62.4 | 2.03 (-1.02, 5.07) | 66.1 | 1.80 (-0.85, 4.45) | 67.8 | 0.68 (0.19, 2.42) | 73.5 | 0.96 (0.20, 4.59) | 47.9 | | TNFiFCP | 2.17 (1.67, 2.82) | 67.2 | 1.78 (1.43, 2.21) | 64.7 | 1.52 (-0.35, 3.39) | 57.7 | 1.28 (-0.39, 2.96) | 57.4 | 1.37 (0.64, 2.92) | 40.6 | 1.19 (0.71, 2.00) | 32.3 | | TNFiFMA | 2.76 (2.31, 3.29) | 89.3 | 2.05 (1.81, 2.33) | 84.8 | 2.35 (1.11, 3.59) | 77.4 | 1.67 (0.59, 2.74) | 68.8 | 1.43 (0.80, 2.55) | 35.8 | 1.23 (0.86, 1.76) | 28.7 |
|
|
